MENU

ARWR Arrowhead Pharmaceuticals Forecast, Technical & Fundamental Analysis

Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company... Show more

Industry: #Biotechnology
A.I.Advisor
Nov 15, 2026

Arrowhead Pharmaceuticals (ARWR) Stock Forecast: RNAi Pipeline and Obesity Readouts Set the Stage for 2027

Key Takeaways

  • Regulatory expansion is the near-term engine: Arrowhead is expected to file a supplemental New Drug Application (sNDA) for plozasiran (REDEMPLO) in severe hypertriglyceridemia (SHTG) before the end of 2026, with a potential accelerated launch as early as mid-2027.
  • Obesity represents a pivotal, higher-upside opportunity: Data from the ARO-INHBE and ARO-ALK7 programs targeting weight loss through RNA interference (RNAi, a mechanism that silences disease-causing genes) are expected to shape the development path in 2026–2027.
  • Strategic positioning is anchored on a validated platform: The company's proprietary TRiM (Targeted RNAi Molecule) technology and a now commercial-stage cardiometabolic franchise give it a differentiated foothold in a competitive RNAi field.
  • Analyst sentiment is broadly constructive: Sell-side coverage carries a consensus "Strong Buy" rating, with an average 12-month price target near $107–$108 and a range spanning roughly $74 to $126, reflecting optimism about the pipeline rather than current profitability.
  • Key macro sensitivities: As a pre-profitability biotech, Arrowhead's valuation remains sensitive to interest rates, capital-market liquidity, and healthcare policy, while its cash position of about $1.6 billion provides a multi-year runway.
  • Risks to watch: Clinical and regulatory execution risk, competition from other RNAi and lipid-lowering developers, and the company's still-negative earnings profile could alter the outlook.
  • For additional context on this company, explore Major News, Today's Price Move, Price Targets, and Earnings on dedicated pages.
  • For automated, AI-driven insights across the market, explore Trending AI Robots.

Strategic Positioning and Competitive Outlook

Arrowhead Pharmaceuticals has transitioned from a pure clinical-stage developer into a commercial-stage RNAi company, a shift that reshapes its medium-term market positioning. Its lead asset, REDEMPLO (plozasiran), is the first and only small interfering RNA (siRNA) therapy approved for familial chylomicronemia syndrome (FCS), a rare genetic disorder causing dangerously elevated triglycerides. Regulatory approvals now span the United States, the European Union, the United Kingdom, Canada, China, and Australia, with the company retaining commercialization rights in most geographies.

The broader strategic value lies in Arrowhead's TRiM platform, which enables precise gene silencing across multiple tissue types, including the liver, lung, muscle, and central nervous system. This versatility underpins a pipeline of roughly 23 clinical candidates and has attracted collaborations with major pharmaceutical partners, including Novartis and Sarepta. Structurally, the company is positioning itself as an emerging cardiometabolic franchise, planning to expand plozasiran into the much larger SHTG population while advancing early-stage obesity and central nervous system programs.

Major Catalysts Ahead

The most consequential near-term catalyst is the planned sNDA filing for plozasiran in SHTG, supported by positive Phase 3 results from the SHASTA-3 and SHASTA-4 trials. Those studies reported median triglyceride reductions of roughly 79% and 81% versus about 27% for placebo, along with a 78% reduction in acute pancreatitis events. Arrowhead has acquired a priority review voucher intended to compress U.S. regulatory review, potentially enabling a launch as early as the second quarter of 2027.

Beyond SHTG, investors are watching the ARO-INHBE and ARO-ALK7 obesity candidates, which target a high-quality weight-loss profile with improved body composition. Additional data are anticipated through 2026, and management has signaled intentions to align with regulators on next steps. Separately, the ARO-DIMER-PA program, which combines PCSK9 and APOC3 targeting for mixed hyperlipidemia, and the zodasiran program for homozygous familial hypercholesterolemia (HoFH) represent further pipeline catalysts into 2027.

Analyst activity has been notably optimistic. Morgan Stanley upgraded Arrowhead to Overweight, while UBS and J.P. Morgan initiated coverage with Buy or Overweight ratings. Firms including Piper Sandler, B. Riley Securities, and H.C. Wainwright have set price targets above $120. The overall trajectory of analyst ratings and price targets has become more constructive through 2026, reflecting growing confidence in the cardiometabolic and obesity franchises.

Industry and Macroeconomic Forces

Arrowhead's trajectory is shaped by several macro forces. As a pre-profitability biotechnology company, its valuation is sensitive to interest rates: higher long-term yields raise the discount rate applied to future cash flows, while a more accommodative rate environment typically supports growth-stage biotech multiples. Broader capital-market liquidity also influences financing conditions and appetite for strategic partnerships and merger-and-acquisition activity across the sector.

On the policy side, drug-pricing dynamics, including provisions of the Inflation Reduction Act in the United States, and evolving payer-reimbursement frameworks in Europe could affect the commercial economics of new launches. Industry-wide, the obesity and cardiometabolic markets remain intensely competitive, with multiple developers pursuing RNAi, peptide, and small-molecule approaches, which raises the bar for differentiation on efficacy, safety, and dosing convenience.

Trend Prediction Engine

Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, exchange-traded fund (ETF), or other asset may trend bullish, bearish, or sideways over the coming week or month. The engine is built to assist users in spotting developing trends, evaluating potential breakouts or reversals, and comparing predictions across a broad range of tradable instruments. It also offers searchable prediction categories, historical context, and alert-oriented functionality to support more timely decision-making. For those tracking names like Arrowhead Pharmaceuticals, the Trend Prediction Engine can serve as a complementary signal alongside fundamental and catalyst-driven research.

2026 Outlook and Long-Term Themes to Watch

Looking toward 2026 and beyond, Arrowhead's long-term narrative centers on the breadth of its RNAi platform and its expansion from rare diseases into larger markets. Successfully broadening plozasiran into SHTG would materially expand the addressable patient population and begin to test the company's commercial infrastructure at scale. The obesity programs represent a structurally larger, but earlier-stage, opportunity where differentiated safety and body-composition data could justify meaningful long-term value.

Cost-structure evolution and margin sustainability will be closely scrutinized as the company scales its commercial organization. While revenue is projected to decline from the elevated partnership-driven level of fiscal 2025, and the company is expected to remain unprofitable in the near term, a cash balance of approximately $1.6 billion offers runway through a catalyst-rich period. Capital-allocation priorities, including disciplined spending and selective partnering, will be central to preserving that runway.

Longer-term themes include the transition of RNAi beyond the liver into central nervous system and muscle tissue, where programs such as ARO-MAPT and ARO-SNCA could open entirely new therapeutic categories. Competitive threats from other RNAi and cardiometabolic players, regulatory developments, and the pace of obesity data maturation will continue to shape consensus expectations. While external analyst price targets cluster well above current levels, they should be read as independent forecasts reflecting pipeline optimism rather than guaranteed outcomes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Interact to see
Advertisement
View a ticker or compare two or three
Interact to see
Advertisement
A.I. Advisor
published Earnings

ARWR is expected to report earnings to fall 55.92% to -134 cents per share on February 10

Arrowhead Pharmaceuticals ARWR Stock Earnings Reports
Q4'26
Est.
$-1.34
Q3'26
Missed
by $1.45
Q2'26
Missed
by $0.16
Q1'26
Beat
by $0.11
Q4'25
Beat
by $0.10
The last earnings report on November 12 showed earnings per share of -303 cents, missing the estimate of -159 cents. With 1.00M shares outstanding, the current market capitalization sits at 8.22B.
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
UTWY39.820.05
+0.11%
US Treasury 20 Year Bond ETF (UTWY)
SRET19.67-0.06
-0.30%
Global X SuperDividend REIT ETF (SRET)
IQLT49.68-0.70
-1.39%
iShares MSCI Intl Quality Factor ETF (IQLT)
UPAR14.44-0.32
-2.17%
UPAR Ultra Risk Parity ETF (UPAR)
TOPT32.84-0.78
-2.32%
iShares Top 20 U.S. Stocks ETF (TOPT)

ARWR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with IONS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then IONS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-7.47%
IONS - ARWR
49%
Loosely correlated
-3.61%
AXON - ARWR
46%
Loosely correlated
-2.85%
TSHA - ARWR
41%
Loosely correlated
-0.98%
AMRN - ARWR
40%
Loosely correlated
-0.62%
CRSP - ARWR
40%
Loosely correlated
-4.43%
More
A.I. Advisor
published General Information

General Information

a developer of novel drugs to treat intractable diseases

Industry Biotechnology

Industry
Biotechnology
Address
177 E Colorado Boulevard
Phone
+1 626 304-3400
Employees
711
Web
https://www.arrowheadpharma.com
Arrowhead Pharmaceuticals (ARWR) Stock Forecast: RNAi Pipeline and Obesity Readouts Set the Stage for 2027